One of the most intensively investigated molecular targets in oncology proves its therapeutic worth for thyroid eye disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Targeted siRNA nanocarrier: a platform technology for cancer treatment
Oncogene Open Access 26 February 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dolgin, E. IGF-1R drugs travel from cancer cradle to Graves’. Nat Biotechnol 38, 385–388 (2020). https://doi.org/10.1038/s41587-020-0481-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-020-0481-8